Description
How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration through toll-like receptor TLR signaling and short-chain fatty acids SCFAs
Resolution criteria
Resolution requires: (1) Mechanistic in vivo study: germ-free mice colonized with Parkinson’s/AD patient-derived dysbiotic microbiota showing TLR4/TLR2 pathway activation in brain (NF-kappaB, NLRP3 inflammasome), with >=2-fold elevation of IL-1beta and IL-18 in hippocampus vs healthy donor-colonized controls; (2) SCFA intervention: oral butyrate or propionate administration (100-300 mg/kg/day) rescues BBB integrity (TEER >=75% of control) and reduces microglial activation (Iba1+ area >=30% reduction) in at least one TLR-signaling-competent model; (3) Bidirectional validation: antibiotics or specific microbiome modulators targeting TLR-activating species reduce both SCFA deficit and neuroinflammatory markers in a dose-dependent manner (EC50 established). Observational microbiome composition studies alone are insufficient.